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Abstract
Background: Acute hypoxemic respiratory failure is one of the leading causes of intensive care unit admission and
is associated with high mortality. Noninvasive oxygenation strategies such as high-flow nasal cannula, standard
oxygen therapy, and noninvasive ventilation (delivered by either face mask or helmet interface) are widely available
interventions applied in these patients. It remains unclear which of these interventions are more effective in
decreasing rates of invasive mechanical ventilation and mortality. The primary objective of this network meta-
analysis is to summarize the evidence and compare the effect of noninvasive oxygenation strategies on mortality
and need for invasive mechanical ventilation in patients with acute hypoxemic respiratory failure.
Methods: We will search key databases for randomized controlled trials assessing the effect of noninvasive
oxygenation strategies in adult patients with acute hypoxemic respiratory failure. We will exclude studies in which
the primary focus is either acute exacerbations of chronic obstructive pulmonary disease or cardiogenic pulmonary
edema. The primary outcome will be all-cause mortality (longest available up to 90 days). The secondary outcomes
will be receipt of invasive mechanical ventilation (longest available up to 30 days). We will assess the risk of bias for
each of the outcomes using the Cochrane Risk of Bias Tool. Bayesian network meta-analyses will be conducted to
obtain pooled estimates of head-to-head comparisons. We will report pairwise and network meta-analysis
treatment effect estimates as risk ratios and 95% credible intervals. Subgroup analyses will be conducted examining
key populations including immunocompromised hosts. Sensitivity analyses will be conducted by excluding those
studies with high risk of bias and different etiologies of acute respiratory failure. We will assess certainty in effect
estimates using GRADE methodology.
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Discussion: This study will help to guide clinical decision-making when caring for adult patients with acute
hypoxemic respiratory failure and improve our understanding of the limitations of the available literature assessing
noninvasive oxygenation strategies in acute hypoxemic respiratory failure.
Systematic review registration: PROSPERO CRD42019121755
Keywords: Hypoxia, Noninvasive ventilation, Oxygen, Oxygen inhalation therapy, Respiratory insufficiency
Background
Acute hypoxemic respiratory failure (AHRF) is among the
leading causes of intensive care unit (ICU) admission in
adult patients, [1], with around 40% of these patients re-
ceiving endotracheal intubation [2, 3]. Invasive mechanical
ventilation (IMV) is associated with adverse events such
as ventilator-associated pneumonia, ventilator-induced
lung injury, and the potential for oversedation [4–6].
Avoiding unnecessary endotracheal intubation remains a
major goal in the management of patients with AHRF [7–
9]. Multiple noninvasive oxygenation strategies have been
identified that might help avoid endotracheal intubation
and decrease mortality, but it remains unclear which of
these is most effective [9].
Previous studies have aimed to identify the optimal initial
oxygenation strategy to avoid the receipt of invasive mech-
anical ventilation in adults with AHRF but have often pro-
duced conflicting results [10–14]. Classically, standard
oxygen therapy (SOT) has been the conventional approach
evaluated. Standard oxygen therapy provides low-flow oxy-
gen (< 15 L/min) using different interfaces such as nasal
prongs, Venturi system, and non-rebreather masks. In the
early 2000s, noninvasive ventilation provided by a face mask
(FM-NIV) was shown to be superior to SOT in two small
single-center randomized controlled trials (RCT) [10, 11]. In
2015, a large RCT failed to show superiority of FM-NIV on
the rates of endotracheal intubation and all-cause mortality
compared to SOT in immunocompromised patients [12].
More recently, the use of high-flow nasal cannula (HFNC)
gained interest and use among clinicians as an alternative
method to provide noninvasive oxygenation [15–17]. A large
3-arm RCT recently compared the efficacy of HFNC, FM-
NIV, and SOT in adults with AHRF [13]. Although this
study did not show a benefit in the primary outcome (inva-
sive mechanical ventilation at 28 days), HFNC was associ-
ated with decreased all-cause mortality at 90 days.
Furthermore, a post hoc subgroup analysis showed that in
patients with severe hypoxemia (PaO2:FiO2 < 200mmHg)
HFNC decreased the need of invasive ventilation when com-
pared with the other two modalities. Notably, the highest
mortality was seen among the FM-NIV treatment arm. This
study started to raise concerns for potential harmful effects
associated with FM-NIV, which were further supported by
two large observational studies [18, 19]. Potential mecha-
nisms of harm attributable to FM-NIV as compared to
HFNC include the poor tolerance of the face-mask interface,
increased risk of patient-ventilator asynchrony, and the in-
ability to limit tidal volumes leading to high transpulmonary
pressures and ventilator- and patient-inflicted lung injury
[20–22]. As a result, recent guidelines have expressed uncer-
tainty regarding the use of FM-NIV for the treatment of de
novo AHRF [7]. Interestingly, in a subsequent study com-
paring HFNC vs SOT among immunocompromised pa-
tients, there were no differences noted in rates of invasive
mechanical ventilation or mortality [14].
The use of a helmet interface to provide NIV (H-NIV)
poses an attractive alternative to provide both oxygen-
ation and ventilation in AHRF, potentially with better
patient tolerability, patient-ventilator interaction, and
the ability to provide ventilation for longer periods of
time [23]. The potential benefits of H-NIV compared to
SOT and FM-NIV to decrease the risk of ETI has been
supported by recent RCTs [24–27]. In an RCT study
conducted in 2010, H-NIV was found to decrease mor-
tality and need for invasive mechanical ventilation com-
pared to SOT in patients with hematologic malignancy
[26]. Helmet-NIV was also found to decrease rates of in-
vasive mechanical ventilation and mortality in a more re-
cent single-center RCT compared to FM-NIV [25].
There are a series of physiologic mechanisms that may
explain these results—predominantly related to the hel-
met interface. The helmet interface may act to decrease
air leaks when compared to the face mask interface. This
may permit more effective delivery of higher levels of
positive end-expiratory pressure potentially increasing
alveolar recruitment and decreasing respiratory drive [2,
8, 22, 27]. Furthermore, patients with AHRF seem to
have better tolerance for a helmet interface minimizing
the time that the therapy requires interruption—some-
thing not uncommon for FM-NIV [25]. Interestingly,
there are currently no available head to head compari-
sons of H-NIV and HFNC for relevant clinical outcomes
such as mortality and need for invasive mechanical
ventilation.
Determining the optimal strategy to decrease rates of
endotracheal intubation in patients with AHRF is essential
to minimize morbidity and mortality associated with the
need for invasive mechanical ventilation. Although HFNC
has become widely used, evidence is lacking regarding its
effect as compared to standard oxygen, and there are no
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head to head comparisons between HFNC and H-NIV.
The limitations of the current evidence are clearly
reflected in clinical practice, where there exists high vari-
ability among clinicians in the use of these four noninva-
sive oxygenation strategies for AHRF [8]. Furthermore,
although previous systematic reviews and meta-analyses
have explored the effectiveness of HFNC in patients with
AHRF, these studies have often pooled control group data
as “any other strategy,” failing to account for the import-
ant physiologic and clinical differences of these alternative
interventions [28–30].
Network meta-analysis (NMA) is a strategy to
summarize the evidence of clinical studies which include
multiple treatments [31]. By incorporating estimates from
direct comparisons and indirect comparisons, NMAs
allow estimation of treatment effects where head to head
comparisons are scarce and can decrease the imprecision
in pooled treatment effects even when head to head com-
parisons exist [32]. To our knowledge, no previous NMAs
have been conducted to compare the relative effectiveness
of all available noinvasive oxygenation strategies among a
general population of adult patients with AHRF.
The primary objective of this NMA is to assess the as-
sociation between different noninvasive oxygenation
strategies and all-cause mortality in adult patients with
AHRF. The secondary objective is to assess the associ-
ation between different noninvasive oxygenation strat-
egies and the receipt of invasive mechanical ventilation
in adult patients with AHRF.
Methods
This protocol has been written in accordance with the
Preferred Reporting Items for Systematic Review and
Meta-Analysis Protocols 2015 statement (PRISMA-P)
and its extension for NMA [33, 34]. This protocol is also
registered in the International Prospective Register of
Systematic Reviews (PROSPERO, CRD42019121755).
Criteria for included studies
Participants and settings
We will include any studies that enrolled adult patients
(18 years of age or older) with AHRF, defined by the
new onset of clinical signs (tachypnea, increased work of
breathing), radiologic signs (unilateral or bilateral chest
x-ray opacities), and gas exchange alterations (different
degrees of hypoxemia). We will consider studies includ-
ing patients treated in the intensive care unit, intermedi-
ate care unit, medical wards, and emergency
department. Studies primarily focused in the treatment
of acute exacerbations of chronic obstructive pulmonary
disease (AE-COPD) or congestive heart failure (CHF)
will be excluded. Specifically, we will exclude such stud-
ies if 50% or more of the included population are pa-
tients with either AE-COPD or CHF, acknowledging
that a lower threshold will exclude too many studies in
the field. Our pre-planned sensitivity analysis will specif-
ically address this issue. The rationale for exclusion is
based in the already shown superiority of noninvasive
ventilation for these conditions. Furthermore, we will
also exclude studies including patients after extubation
for major thoracic surgery.
Interventions and comparators
All interventions considered in this review are noninva-
sive oxygenation strategies. HFNC oxygenation refers to
oxygen delivered through a nasal cannula, at a FIO2 up
to 1.0 and a flow rate that can be as high as 60 l/min.
NIV provides positive pressure ventilation that can be
delivered with different modalities: continuous positive
airway pressure, bi-level positive airway pressure, or
pressure support ventilation. The interfaces used can be
either a face mask (FM-NIV) or a helmet (H-NIV).
Given the potential differences in reported outcomes,
these interfaces will be considered as two different inter-
ventions in the network. SOT (low-flow systems) com-
prise traditional nasal cannula, Venturi system masks, or
non-rebreather masks. All of these modalities can pro-
vide oxygen at low flow (< 15 l/min) with varying levels
of FIO2.
Outcomes measures
The primary outcome of this study will be all-cause
mortality, defined as the longest available in the first 90
days after randomization. The secondary outcome will
be receipt of invasive mechanical ventilation (longest
available at 30 days). Given that the criteria for endo-
tracheal intubation might vary between studies, we will
collect information on whether decisions to intubate
were based on pre-specified criteria or not.
Study design and publication types
We will include only randomized controlled trials fo-
cused on the treatment of acute hypoxemic respiratory
failure if a combination of any of these interventions was
assessed: HFNC, FM-NIV, H-NIV, and SOT.
Information sources and search strategy
The following seven electronic bibliographic databases
will be searched using a comprehensive search strategy
developed by an information specialist (MR): (1) Ovid
MEDLINE, (2) Ovid EMBASE, (3) PubMed (non-MED-
LINE records only), (4) Ovid EBM Reviews-Cochrane
Central Register of Controlled Trials, (5) EBSCO
CINAHL Complete, (6) Web of Science, and (7) LILACS.
We will also search ClinicalTrials.gov, WHO Inter-
national Clinical Trials Registry Platform, and Inter-
national Standard Randomized Controlled Trial
Number Registry for all registered clinical trials and
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randomized controlled trials. The search strategy will
be structured according to the Peer Reviewed Elec-
tronic Search Strategies (PRESS) 2015 Guidelines [35]
(refer to Supplementary File for full search strategy).
We will use a validated search filter for randomized
controlled trials from the Cochrane Handbook for Sys-
tematic Reviews of Interventions Version 5.1.0, Section
6.4.11 [36] to screen Ovid MEDLINE, Ovid EMBASE,
and PubMed. We will adapt a pre-tested search filter
for randomized controlled trials from the Scottish
Intercollegiate Guidelines Network [37] for EBSCO
CINAHL Complete and Web of Science. No limits will
be applied to language, publication year, gender or
race. We will manage all references and duplicates
using EndNote X8 citation management software.
Study selection
Two reviewers (BLF and FA) will screen independently
the titles and abstracts retrieved from the search strategy
and the additional sources in order to identify those
meeting the mentioned eligibility criteria. Subsequently,
we will obtain full texts of the articles meeting these
pre-specified criteria and review again in a second stage.
Any disagreement between the reviewers will be dis-
cussed and referred to final decision by a third investiga-
tor (LM, HW, DS).
Data extraction
The two reviewers (BLF and FA) will perform data ex-
traction independently in a pre-piloted data extraction
form created in Excel (Microsoft®). Any differences will
be resolved by consensus or discussion with a third au-
thor (LM). Abstracted data will include study character-
istics (trial design, size, and funding source), patients’
characteristics (age, sex, etiology of AHRF, immunocom-
promised status, and the presence of severe AHRF
(PaO2:FIO2 ratio < 200)), details of the interventions (lo-
cation of application, duration of the exposure to each of
the oxygenation strategy, type of noninvasive ventilation
modality), outcome data for each endpoint of interest.
Risk of bias assessment
The risk of bias will be assessed independently using the
tools specified in the Cochrane Handbook for Systematic
Reviews of Interventions for RCTs [27–30]. The following
aspects will be assessed: (1) random sequence generation
(selection bias), (2) allocation concealment (selection bias),
(3) blinding of participants and personnel (performance
bias), (4) blinding of outcome assessment (detection bias),
(5) incomplete outcome data, (6) selective reporting
(reporting bias), and (7) other sources of bias.
Patient and public involvement
This research will be done without patient involvement.
Patients will not be invited to comment on the protocol
design nor consulted to develop patient-relevant
outcomes.
Data synthesis and analysis
We will summarize the included studies based on study
and patient characteristics, outcome measures, and risk
of bias. We will perform a series of pairwise Bayesian
meta-analyses with a random-effects model, followed by
a network meta-analysis using a Bayesian framework to
derive head-to-head treatment effect estimates compar-
ing all interventions. Analyses will be based on Markov
chain Monte Carlo methods using prior distributions for
event rates derived from previous literature, minimally
informative treatment effect estimates, and informative
prior distributions for heterogeneity estimates derived
from external evidence [38]. We will report pairwise and
NMA treatment effect estimates as risk ratios (RR), esti-
mating summary treatment effect estimates from the
median and corresponding 95% credible intervals (CrIs)
from the 2.5th and 97.5th percentile of the posterior dis-
tribution. We will also rank interventions according to
their apparent effectiveness and will calculate the prob-
ability that interventions have risk reductions or in-
creases greater compared to standard oxygen therapy.
We will quantify heterogeneity in treatment effects be-
tween studies using the posterior distribution τ2. Incon-
sistency (incoherence) between direct and indirect
comparisons will be estimated using the node-splitting
approach contrasting estimates from both direct and in-
direct evidence [39, 40]. We will visually assess model
convergence using the Brooks-Gelman-Rubin diagnostic,
trace plots, and auto-correlation plots. We will assess
the goodness-of-fit of our final models by comparing the
mean residual deviance with the number of contributing
data points, calculating the percentage of standardized
node-based residuals within 1.96 of the standard normal
distribution, and visually inspecting the distribution of
residuals on Q-Q plots. We will perform all analyses in
R v3.6 and OpenBUGS.
Assessment of publication bias
We will assess for the presence of publication bias by
examining the comparison-adjusted funnel plot [41]. We
will examine the shape of the funnel plot and assume
that there is a risk of publication bias if its shape is
asymmetrical. We will formally test for asymmetry in
the funnel plot by performing the Harbord’s test [42].
Subgroup analysis
Where information is available, we will assess for cred-
ible subgroup effects using a random-effects NMA meta-
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regression Bayesian model to determine whether the esti-
mated treatment effects are affected by the following fac-
tors: (1) severe AHRF (PaO2:FIO2 ratio < 200) vs less
severe AHRF (PF ratio > 200), hypothesizing that HFNC
is better than SOT for patients with severe AHRF, and (2)
immunocompromised patients (hematologic malignancies,
solid tumors with active chemotherapy, treatment with
immunosuppressant drugs, and solid organ transplant
recipients) vs non-immunocompromised patients, hy-
pothesizing that NIV may be more effective in immuno-
compromised patients.
Sensitivity analysis
We will perform sensitivity analysis for the treatment ef-
fect estimates by excluding studies with high risk of bias
in each of the assessed items. Furthermore, we will con-
duct a sensitivity analysis by excluding those studies that
included any patients with AE-COPD or CHF, and with
non-informative prior distributions for the heterogeneity
parameters.
Grading of recommendations
We will rate the quality of each direct, indirect, and
NMA estimates based on the four-step approach sug-
gested by the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) Working Group
[43]. The network effect estimates for each of the poten-
tial comparisons and every outcome, along with the
GRADE rating for certainty in the evidence, will be
depicted in a summary of findings table.
Discussion
In summary, this Bayesian network meta-analysis will
provide a comprehensive summary of the direct and in-
direct evidence on the efficacy of different noninvasive
oxygenation strategies to prevent mortality and the re-
ceipt of invasive mechanical ventilation in adult patients
with acute hypoxemic respiratory failure. The current
protocol was written in accordance with the Preferred
Reporting Items for Systematic Review and Meta-
Analysis Protocols 2015 statement (PRISMA-P) and its
extension for NMA. This protocol is also registered in
the International Prospective Register of Systematic Re-
views (PROSPERO). The overall quality of the evidence
will be assessed using the Grading of Recommendations
Assessment Development and Evaluation (GRADE)
approach.
We expect this study will help with clinical decision-
making when caring for adult patients with AHRF. Fur-
thermore, the systematic approach will improve our un-
derstanding of the limitations of the available literature
to inform the treatment of patients with AHRF. Finally,
we believe that our results will help identify predictive
enrichment strategies that may improve the design of fu-
ture randomized controlled trials.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13643-020-01363-0.
Additional file 1. NMA-CRFRI.
Abbreviations
AHRF: Acute hypoxemic respiratory failure; ICU: Intensive care unit;
IMV: Invasive mechanical ventilation; SOT: Standard oxygen therapy; FM-
NIV: Face mask noninvasive ventilation; RCT: Randomized controlled trial;
HFNC: High-flow nasal cannula; H-NIV: Helmet noninvasive ventilation;
NMA: Network meta-analysis; AE-COPD: Acute exacerbation of chronic
obstructive pulmonary disease; CHF: Congestive heart failure
Authors’ contributions
BLF, FA, LM, HW, and DS conceived the study. LDS and NDF contributed
with the clinical background and expertise. BR, RS, and BDC contributed with
the analytical plan and the bias assessment approach. MR performed the
literature search plan. BLF, FA, LM, and DS drafted the protocol. All authors
revised the protocol and approved the final version. DS supervised the study.
Funding
Dr. Bruno Ferreyro is supported by a Vanier Canada Graduate Scholarship.
Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated
or analyzed during the current protocol.
Ethics approval and consent to participate
This study will not include individual patient data. Therefore, ethical approval
will not be required to conduct this SR and NMA. We expect that the
findings of this study will be disseminated through presentation in national
and international conferences and publication in peer review journals.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no conflict of interest relevant to the
contents of this manuscript.
Author details
1Interdepartmental Division of Critical Care Medicine, University of Toronto,
Toronto, ON, Canada. 2Institute of Health Policy, Management and
Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto,
Canada. 3Department of Medicine, Sinai Health System and University Health
Network, Toronto, Canada. 4Department of Critical Care Medicine,
Sunnybrook Health Sciences Centre, Toronto, Canada. 5Division of
Respirology, Department of Medicine, University Health Network and
University of Toronto, Toronto, Canada. 6Department of Medicine, Division of
Critical Care, McMaster University, Hamilton, Canada. 7Department of Health
Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON,
Canada. 8Sidney Liswood Health Sciences Library, Sinai Health System,
Toronto, Canada. 9Institute for Clinical Evaluative Sciences, Toronto, Ontario,
Canada. 10Applied Health Research Center (AHRC), Li Ka Shing Knowledge
Institute, St. Michael’s Hospital, Toronto, Canada. 11Institute of Primary Health
Care (BIHAM), University of Bern, Bern, Switzerland.
Received: 13 February 2020 Accepted: 14 April 2020
References
1. Scala R, Heunks L. Highlights in acute respiratory failure. Eur Respir Rev.
2018;27(147):180008.
2. Nava S, Hill N. Noninvasive ventilation in acute respiratory failure. Lancet.
2009;374(9685):250–9.
Ferreyro et al. Systematic Reviews            (2020) 9:95 Page 5 of 6
3. de Jong A, Calvet L, Lemiale V, Demoule A, Mokart D, Darmon M, et al.
The challenge of avoiding intubation in immunocompromised patients
with acute respiratory failure. Expert Review of Respiratory Medicine
2018;0(0):1-14.
4. Strøm T, Toft P. Sedation and analgesia in mechanical ventilation. Semin
Respir Crit Care Med. 2014;35(4):441–50.
5. Slutsky AS, Ranieri VM. Ventilator-induced lung injury. N Engl J Med. 2013;
369(22):2126–36.
6. Kalanuria AA, Ziai W, Mirski M. Ventilator-associated pneumonia in the ICU.
Crit Care. 2014;18(2):208.
7. Rochwerg B, Brochard L, Elliott MW, Hess D, Hill NS, Nava S, et al. Official
ERS/ATS clinical practice guidelines: noninvasive ventilation for acute
respiratory failure. European Respiratory Journal. 2017;50(2).
8. Garcia-de-Acilu M, Patel BK, Roca O. Noninvasive approach for de novo
acute hypoxemic respiratory failure: noninvasive ventilation, high-flow nasal
cannula, both or none? Curr Opin Crit Care. 2019;25(1):54–62.
9. Dugan KC, Hall JB, Patel BK. High-flow nasal oxygen-the pendulum
continues to swing in the assessment of critical care technology. JAMA.
2018;320(20):2083–4.
10. Hilbert G, Gruson D, Vargas F, Valentino R, Gbikpi-Benissan G, Dupon M,
et al. Noninvasive ventilation in immunosuppressed patients with
pulmonary infiltrates, fever, and acute respiratory failure. N Engl J Med.
2001;344(7):481–7.
11. Antonelli M, Conti G, Bufi M, Costa MG, Lappa A, Rocco M, et al.
Noninvasive ventilation for treatment of acute respiratory failure in patients
undergoing solid organ transplantation: a randomized trial. JAMA. 2000;
283(2):235–41.
12. Lemiale V, Mokart D, Resche-Rigon M, Pène F, Mayaux J, Faucher E, et al.
Effect of noninvasive ventilation vs oxygen therapy on mortality among
immunocompromised patients with acute respiratory failure. JAMA. 2015;
314(16):1711–9.
13. Frat J-P, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, et al. High-flow
oxygen through nasal cannula in acute hypoxemic respiratory failure. N
Engl J Med. 2015;372(23):2185–96.
14. Azoulay E, Lemiale V, Mokart D, Nseir S, Argaud L, Pene F, et al. Effect of
high-flow nasal oxygen vs standard pxygen on 28-day mortality in
immunocompromised patients with acute respiratory failure: the HIGH
randomized clinical trial. JAMA. 2018;320(20):2099–107.
15. Goligher EC, Slutsky AS. Not just oxygen? Mechanisms of benefit from high-
flow nasal cannula in hypoxemic respiratory failure. Am J Respir Crit Care
Med. 2017;195(9):1128–31.
16. Coudroy R, Jamet A, Petua P, Robert R, Frat J-P, Thille AW. High-flow nasal
cannula oxygen therapy versus noninvasive ventilation in
immunocompromised patients with acute respiratory failure: an
observational cohort study. Ann Intensive Care. 2016;6(1):1–11.
17. Nishimura M. High-flow nasal cannula oxygen therapy in adults. J Intensive
Care. 2015;3(1):15.
18. Bellani G, Laffey JG, Pham T, Madotto F, Fan E, Brochard L, et al. Noninvasive
ventilation of patients with acute respiratory distress syndrome. Insights
from the LUNG SAFE study. Am J Respir Crit Care Med. 2017;195(1):67–77.
19. Carteaux G, Millán-Guilarte T, De Prost N, Razazi K, Abid S, Thille AW, et al.
Failure of noninvasive ventilation for de novo acute hypoxemic respiratory
failure: role of tidal volume. Crit Care Med. 2016;44(2):282–90.
20. Brochard L, Slutsky A, Pesenti A. Mechanical ventilation to minimize
progression of lung injury in acute respiratory failure. Am J Respir Crit Care
Med. 2017;195(4):438–42.
21. Carteaux G, Lyazidi A, Cordoba-Izquierdo A, Vignaux L, Jolliet P, Thille AW,
et al. Patient-ventilator asynchrony during noninvasive ventilation: a bench
and clinical study. Chest. 2012;142(2):367–76.
22. Grieco DL, Menga LS, Eleuteri D, Antonelli M. Patient self-inflicted lung
injury: implications for acute hypoxemic respiratory failure and ARDS
patients on noninvasive support. Minerva Anestesiol. 2019;85(9):1014–23.
23. Esquinas Rodriguez AM, Papadakos PJ, Carron M, Cosentini R, Chiumello D.
Clinical review: helmet and noninvasive mechanical ventilation in critically ill
patients. Critical care (London, England). 2013;17(2):223.
24. Brambilla AM, Aliberti S, Prina E, Nicoli F, Del Forno M, Nava S, et al. Helmet
CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to
pneumonia. Intensive Care Med. 2014;40(7):942–9.
25. Patel BK, Wolfe KS, Pohlman AS, Hall JB, Kress JP. Effect of noninvasive
ventilation delivered by helmet vs face mask on the rate of endotracheal
intubation in patients with acute respiratory distress syndrome. JAMA. 2016;
315(22):2435–7.
26. Squadrone V, Massaia M, Bruno B, Marmont F, Falda M, Bagna C, et al. Early
CPAP prevents evolution of acute lung injury in patients with hematologic
malignancy. Intensive Care Med. 2010;36(10):1666–74.
27. 33rd Congress of the Scandinavian Society of Anaesthesiology and
Intensive Care Medicine. Acta anaesthesiologica scandinavica. 2015;59.
28. Algamdi M, Ball I. High flow nasal cannula oxygen therapy for acute
hypoxemic respiratory failure: a systematic review. Chest. 2016;150(4):306A.
29. Lin S-M, Liu K-X, Lin Z-H, Lin P-H. Does high-flow nasal cannula oxygen
improve outcome in acute hypoxemic respiratory failure? A systematic
review and meta-analysis. Respir Med. 2017;131:58–64.
30. Sklar MC, Mohammed A, Orchanian-Cheff A, Del Sorbo L, Mehta S, Munshi
L. The impact of high-flow nasal oxygen in the immunocompromised
critically ill: a systematic review and meta-analysis. Respir Care. 2018;63(12):
1555–66.
31. Brignardello-Petersen R, Rochwerg B, Guyatt GH. What is a network meta-
analysis and how can we use it to inform clinical practice? Pol Arch Med
Wewn. 2014;124(12):659–60.
32. Greco T, Biondi-Zoccai G, Saleh O, Pasin L, Cabrini L, Zangrillo A, et al. The
attractiveness of network meta-analysis: a comprehensive systematic and
narrative review. Heart Lung Vessel. 2015;7(2):133–42.
33. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al.
Preferred reporting items for systematic review and meta-analysis protocols
(PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
34. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al.
The PRISMA extension statement for reporting of systematic reviews
incorporating network meta-analyses of health care interventions: checklist
and explanations. Ann Intern Med. 2015;162(11):777–84.
35. McGowan J, Sampson M, Salzwedel DM, et al. PRESS Peer Review of Electronic
Search Strategies: 2015 guideline statement. Journal of Clinical Epidemiology.
201;75:40-46. doi.org/https://doi.org/10.1016/j.jclinepi.2016.01.021.
36. Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of
interventions Version 5.1.0 [updated March 2011]. The Cochrane
Collaboration, 2011. Available from www.handbook.cochrane.org.
37. Scottish Intercollegiate Guidelines Network (SIGN). Randomised controlled
trials search filter. Healthcare Improvement Scotland. [undated]. Available
from: https://www.sign.ac.uk/search-filters.html.
38. Turner RM, Jackson D, Wei Y, Thompson SG, Higgins JP. Predictive
distributions for between-study heterogeneity and simple methods for their
application in Bayesian meta-analysis. Stat Med. 2015;34(6):984–98.
39. van Valkenhoef G, Dias S, Ades AE, Welton NJ. Automated generation of
node-splitting models for assessment of inconsistency in network meta-
analysis. Res Synth Methods. 2016;7(1):80–93.
40. Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and
inconsistency in network meta-analysis: concepts and models for multi-arm
studies. Res Synth Methods. 2012;3(2):98–110.
41. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools
for network meta-analysis in STATA. PLoS One. 2013;8(10):e76654.
42. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in
meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;
25(20):3443–57.
43. Puhan MA, Schunemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh
JA, et al. A GRADE working group approach for rating the quality of
treatment effect estimates from network meta-analysis. BMJ. 2014;349:
g5630.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Ferreyro et al. Systematic Reviews            (2020) 9:95 Page 6 of 6
